Literature DB >> 27814824

ACR Appropriateness Criteria® Stage I Breast Carcinoma.

Phan Tuong Huynh1, Sergy V Lemeshko2, Mary C Mahoney3, Mary S Newell4, Lisa Bailey5, Lora D Barke6, Carl D'Orsi4, Jennifer A Harvey7, Mary K Hayes8, Peter M Jokich9, Su-Ju Lee3, Constance D Lehman10, Martha B Mainiero11, David A Mankoff12, Samir B Patel13, Handel E Reynolds14, M Linda Sutherland15, Bruce G Haffty16.   

Abstract

Stage I breast carcinoma is classified when an invasive breast carcinoma is ≤2 cm in diameter (T1), with no regional (axillary) lymph node metastases (N0) and no distant metastases (M0). The most common sites for metastases from breast cancer are the skeleton, lung, liver, and brain. In general, women and health care professionals prefer intensive screening and surveillance after a diagnosis of breast cancer. Screening protocols include conventional imaging such as chest radiography, bone scan, ultrasound of the liver, and MRI of brain. It is uncertain whether PET/CT will serve as a replacement for current imaging technologies. However, there are no survival or quality-of-life differences for women who undergo intensive screening and surveillance after a diagnosis of stage I breast carcinoma compared with those who do not. The ACR Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Copyright © 2012 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Appropriateness criteria; early breast cancer; surveillance protocol

Mesh:

Year:  2016        PMID: 27814824     DOI: 10.1016/j.jacr.2016.09.024

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  1 in total

Review 1.  Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications.

Authors:  Andria Hadjipanteli; Paul Doolan; Efthyvoulos Kyriacou; Anastasia Constantinidou
Journal:  Cancer Manag Res       Date:  2020-10-12       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.